Streetbeat News

HWEL

Healthwell Acquisition Corp I

Open

10.48

Mkt cap

327M

Volume

1.1K

High

10.48

P/E Ratio

28.31

52-wk high

11.88

Low

10.47

Div yield

N/A

52-wk low

9.14

Healthwell Acquisition Corp. I (NASDAQ:HWEL) has cancelled its special stockholder meeting scheduled for December 4, 2023, and withdrawn the proposals from its November 13, 2023 SEC filing. The company plans to liquidate, ceasing all operations except for winding up. Healthwell will redeem its Class A common stock at an estimated price of $10.50 per share from its IPO trust account, extinguishing stockholder rights. Warrants will expire worthless, and Healthwell's sponsor waived redemption rights for Class B common stock. The liquidation and dissolution are subject to Delaware law and other legal requirements. The liquidation process will be managed by Continental Stock Transfer & Trust Company, with the redemption expected within ten business days after commencement.

Portfolio Pulse from Benzinga Newsdesk

November 19, 2023 | 8:29 pm

Healthwell Acquisition has postponed the special meeting of the company's stockholders to approve its proposed business combination with Starton Therapeutics. The meeting was originally scheduled for October 25, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 6:54 am

Starton Therapeutics, the combination partner of Healthwell Acquisition Corp. I (HWEL), has dosed its first patient in the STAR-LLD Lenalidomide Phase 1b clinical trial for multiple myeloma.

Portfolio Pulse from Bill Haddad

October 04, 2023 | 12:11 pm

Starton Therapeutics has received FDA authorization to proceed with its Phase 1b STAR-LLD clinical trial for multiple myeloma. The treatment will replace oral Revlimid with STAR-LLD and will be combined with Velcade and dexamethasone. Starton has signed an agreement for a business combination with Healthwell Acquisition Corp. I (NASDAQ:HWEL).

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 8:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.